Market Cap 227.31M
Revenue (ttm) 1.55M
Net Income (ttm) -63.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -4,068.39%
Debt to Equity Ratio 0.00
Volume 5,212,924
Avg Vol 2,072,334
Day's Range N/A - N/A
Shares Out 119.64M
Stochastic %K 53%
Beta 1.04
Analysts Strong Sell
Price Target $6.50

Company Profile

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a...

Industry: Biotechnology
Sector: Healthcare
Phone: 514 336 0444
Address:
1111 Dr. Frederik-Philips Boulevard, Suite 420, Montreal, Canada
MarketBeat
MarketBeat May. 13 at 6:11 PM
https://marketbeat.com/a/8652816/ $MIST Milestone Pharmaceuticals Q1 Earnings Call Highlights
0 · Reply
doctorhak
doctorhak May. 13 at 5:57 PM
$MIST PIP has NEVER been studied outpatient, double blind, placebo. It’s NOT even a viable alternative for these patients who as a group respond better to earlier intervention. Any adverse event from PIP will no doubt be met with medical malpractice. So best of luck saving pennies. Knowledgeable providers know that PIP is off label. That’s a real risk to outpatient unmonitored therapy. Furthermore have any of you ever experienced tachycardia personal or attempted to treat it? WTF do you really know about the medical condition?
0 · Reply
TheYoungGeologist
TheYoungGeologist May. 13 at 5:57 PM
$MIST now have 10000 shares in my brokerage and 7000 in my Roth IRA
1 · Reply
Wut_About_Bob
Wut_About_Bob May. 13 at 5:32 PM
$MIST Blocking this obvious short. He has a shady handle name, and all of his posts are negative. It's quite obvious he hasn't researched the organization with most of what he has said. Block those who appear on a board to intentionally deceive.
0 · Reply
Amb8675309
Amb8675309 May. 13 at 5:18 PM
$MIST really it’s a binary outcome for the next earnings call hiding inside of a slow, cash burn problem
0 · Reply
Amb8675309
Amb8675309 May. 13 at 5:17 PM
$MIST the biggest driver for the share price will be if we get to see that 2000 to 3000 scripts on the next earning call
1 · Reply
Bolekjol
Bolekjol May. 13 at 4:43 PM
$MIST now it will be a lot of focus on afib updates, enrollment etc. It will multiply before readouts afib deal is huge with very high probability of success. Just load the deeps when can and let it run.
0 · Reply
CashisKing_
CashisKing_ May. 13 at 4:43 PM
$MIST when are we expecting china aproval?
1 · Reply
kellymone2
kellymone2 May. 13 at 4:36 PM
$MIST told ya. Panic doesn't bring anything.
0 · Reply
KilroyPicks
KilroyPicks May. 13 at 4:26 PM
$MIST - I would reasonably expect revenue between $700,000 to $1.1 million for Q2. Q3 I would expect a revenue range between $2.2 Million and $3.2 Million and Q4 between $4 Million and $5.5 Million. Full year revenue between $7.13 Million and $10 Million on the high side. Hopefully the scripts accelerate faster than I predict. Based on my expectations the scripts volume needed are as follows. Q2 - 1,400 to 2,200 Q3 - 4,400 to 6,400 Q4 - 8,000 to 11,000
1 · Reply
Latest News on MIST
Milestone Pharmaceuticals reports Q1 EPS (20c), consensus 19c

2026-05-13T12:41:15.000Z - 7 hours ago

Milestone Pharmaceuticals reports Q1 EPS (20c), consensus 19c


Milestone Pharmaceuticals Earnings Call Transcript: Q1 2026

May 13, 2026, 8:30 AM EDT - 8 hours ago

Milestone Pharmaceuticals Earnings Call Transcript: Q1 2026


Milestone Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 20, 2026, 8:30 AM EDT - 7 weeks ago

Milestone Pharmaceuticals Earnings Call Transcript: Q4 2025


Milestone Pharmaceuticals to present Cardamyst data at ACC 26

2026-03-16T12:23:37.000Z - 2 months ago

Milestone Pharmaceuticals to present Cardamyst data at ACC 26


Milestone Pharmaceuticals upgraded to Buy from Hold at TD Cowen

2025-12-15T15:05:16.000Z - 5 months ago

Milestone Pharmaceuticals upgraded to Buy from Hold at TD Cowen


Milestone Pharmaceuticals Transcript: FDA Announcement

Dec 15, 2025, 8:00 AM EST - 5 months ago

Milestone Pharmaceuticals Transcript: FDA Announcement


Milestone Pharmaceuticals receives FDA approval of CARDAMYST

2025-12-14T16:30:25.000Z - 5 months ago

Milestone Pharmaceuticals receives FDA approval of CARDAMYST


Milestone Pharmaceuticals trading halted, news pending

2025-12-12T23:10:17.000Z - 5 months ago

Milestone Pharmaceuticals trading halted, news pending


Milestone® Pharmaceuticals to Present at Upcoming Conferences

Aug 19, 2025, 8:00 AM EDT - 9 months ago

Milestone® Pharmaceuticals to Present at Upcoming Conferences


Milestone Pharmaceuticals Announces Proposed Public Offering

Jul 11, 2025, 6:01 AM EDT - 10 months ago

Milestone Pharmaceuticals Announces Proposed Public Offering


FDA Issues Complete Response Letter for Etripamil for PSVT

Mar 28, 2025, 7:00 AM EDT - 1 year ago

FDA Issues Complete Response Letter for Etripamil for PSVT


Milestone Pharmaceuticals Transcript: Investor update

Feb 25, 2025, 10:30 AM EST - 1 year ago

Milestone Pharmaceuticals Transcript: Investor update


Milestone Pharmaceuticals Transcript: Study update

Jun 20, 2024, 8:00 AM EDT - 2 years ago

Milestone Pharmaceuticals Transcript: Study update


MarketBeat
MarketBeat May. 13 at 6:11 PM
https://marketbeat.com/a/8652816/ $MIST Milestone Pharmaceuticals Q1 Earnings Call Highlights
0 · Reply
doctorhak
doctorhak May. 13 at 5:57 PM
$MIST PIP has NEVER been studied outpatient, double blind, placebo. It’s NOT even a viable alternative for these patients who as a group respond better to earlier intervention. Any adverse event from PIP will no doubt be met with medical malpractice. So best of luck saving pennies. Knowledgeable providers know that PIP is off label. That’s a real risk to outpatient unmonitored therapy. Furthermore have any of you ever experienced tachycardia personal or attempted to treat it? WTF do you really know about the medical condition?
0 · Reply
TheYoungGeologist
TheYoungGeologist May. 13 at 5:57 PM
$MIST now have 10000 shares in my brokerage and 7000 in my Roth IRA
1 · Reply
Wut_About_Bob
Wut_About_Bob May. 13 at 5:32 PM
$MIST Blocking this obvious short. He has a shady handle name, and all of his posts are negative. It's quite obvious he hasn't researched the organization with most of what he has said. Block those who appear on a board to intentionally deceive.
0 · Reply
Amb8675309
Amb8675309 May. 13 at 5:18 PM
$MIST really it’s a binary outcome for the next earnings call hiding inside of a slow, cash burn problem
0 · Reply
Amb8675309
Amb8675309 May. 13 at 5:17 PM
$MIST the biggest driver for the share price will be if we get to see that 2000 to 3000 scripts on the next earning call
1 · Reply
Bolekjol
Bolekjol May. 13 at 4:43 PM
$MIST now it will be a lot of focus on afib updates, enrollment etc. It will multiply before readouts afib deal is huge with very high probability of success. Just load the deeps when can and let it run.
0 · Reply
CashisKing_
CashisKing_ May. 13 at 4:43 PM
$MIST when are we expecting china aproval?
1 · Reply
kellymone2
kellymone2 May. 13 at 4:36 PM
$MIST told ya. Panic doesn't bring anything.
0 · Reply
KilroyPicks
KilroyPicks May. 13 at 4:26 PM
$MIST - I would reasonably expect revenue between $700,000 to $1.1 million for Q2. Q3 I would expect a revenue range between $2.2 Million and $3.2 Million and Q4 between $4 Million and $5.5 Million. Full year revenue between $7.13 Million and $10 Million on the high side. Hopefully the scripts accelerate faster than I predict. Based on my expectations the scripts volume needed are as follows. Q2 - 1,400 to 2,200 Q3 - 4,400 to 6,400 Q4 - 8,000 to 11,000
1 · Reply
aak12345
aak12345 May. 13 at 4:19 PM
$MIST don't see anything wrong with progress. Afib trial started (2 years to complete) Express scripts onboard already (others to follow soon) Scripts steadily rising in early data Ample cash reserves China +EU approval incoming
1 · Reply
Diverstj981
Diverstj981 May. 13 at 4:17 PM
$MIST at the end of March there was a dead cat bounce before it bottomed. I'm sitting tight for a day or two longer before adding in case history repeats itself.
0 · Reply
Joe_BLow_88
Joe_BLow_88 May. 13 at 4:10 PM
$MIST 400 unique prescribers! that is an outstanding number. Actual April prescriptions 450, over about 150 to march 20. Their marketing scheme is working really well. Docs are prescribing. There's breadth in those numbers. This may hockey stick if they keep it up. and their burn rate is reasonable. No insurer push back, so far. Afib trial on the way. But they are Canadians. So I understand the hesitation. I'll hold for now.
1 · Reply
Amb8675309
Amb8675309 May. 13 at 3:36 PM
$MIST after they were approved, people discussed pill in a pocket as a cheap alternative. Remember if you use super cheap PIP and you time how long it takes to bring your heart rate down and then you look at Cardamyst & how many people end up having to use the 2nd dose before their heart rate goes back down there’s only a delta of approx 10 minutes. PIP is pennies on the dollar. Took advice of someone who didn’t understand what pill in the pocket was plus he thought that sales were going to be good. Do your own DD folks. this particular leadership team is sloppy( which is why they got their first CRL last year). Cardamyst has a tough uphill battle based on cost per dose vs PIP option. when people say this will cut down ER visits: by the time you’re waited 3 hours at the ER, you could’ve just used PIP and not had to pay $1500 for Cardamyst, and not had to go to ER. If you’re undiagnosed PVST/aFib, sure, go to ER. Will ER give you Cardamyst?
2 · Reply
Amb8675309
Amb8675309 May. 13 at 3:22 PM
$MIST I asked someone if this was bec there’s pill in a pocket as a cheaper option- he hadn’t done the homework and told me he thought sakes would be great…. Learning to trust my own gut-
1 · Reply
KilroyPicks
KilroyPicks May. 13 at 2:16 PM
$MIST - https://www.minichart.com.sg/2026/04/28/everest-medicines-supplemental-announcement-on-discloseable-asset-purchase-agreement-and-psvt-nasal-spray-product-commercialization-12/
0 · Reply
durocali
durocali May. 13 at 2:15 PM
$MIST agreed. shares fell there less than 7 wks ago... and managed to double up in short order. market knows the potential here. and yes 2H26 and likely greater upside in 2027-28... here for it.
1 · Reply
KilroyPicks
KilroyPicks May. 13 at 2:14 PM
$MIST https://www.biospectrumasia.com/news/25/27391/everest-medicines-inks-50-m-deal-with-corxel-pharma-to-develop-nasal-spray-in-greater-china.html
0 · Reply
KilroyPicks
KilroyPicks May. 13 at 2:12 PM
$MIST https://www.tipranks.com/news/company-announcements/everest-medicines-details-psvt-asset-purchase-and-readies-for-china-launch
0 · Reply
KilroyPicks
KilroyPicks May. 13 at 2:12 PM
$MIST - Everest Medicines will pay a royalty payment of $105 Million was drug gets China approval which is expected in Q3.
0 · Reply
kgstocker68
kgstocker68 May. 13 at 2:11 PM
$MIST Wow, pretty light sales so far. This might be a very slow trek uphill. Will Q2 break $1M?
2 · Reply
Vincybull
Vincybull May. 13 at 2:11 PM
$MIST Did they say when phase 3 of the AFib RvR trial will start? They said for the apoeovaion in CHINA. Who said that 30M were expected for this quarter? There is great manipulation, those great sons of . .
1 · Reply